[23] CHAPTER X LESSON 1 Flashcards
is a broad term that encompasses all aspects of the transfusion of patients.
“Transfusion therapy”
Each blood component has specific indications for
use, expected outcomes, and other considerations
are considered drugs because of their use in treating diseases
Blood and blood products
The transfusion of blood cells is also [?], in that the cells must survive and function after transfusion to have a therapeutic effect.
transplantation
Transfusion therapy is used primarily to treat two conditions:
inadequate oxygen-carrying capacity because of anemia or blood loss and insufficient coagulation proteins or platelets to provide adequate hemostasis.
Preparation: Approx. 450mL of blood with anticoagulant (CPD or CPDA-1)
Whole Blood
Shelf life: CPD- 21 days at 1 to 6 degrees Celsius; CPDA-1: 35 days
Whole Blood
A unit of blood must be transfused within 24 hours if the seal on the bag is broken to remove plasma.
Whole Blood
Dilution: Eight parts circulating blood to one-part anticoagulant (8:1)
Whole Blood
Composition: RBC, plasma, WBC and platelets
Whole Blood
Indication: replace the loss of both RBC mass and plasma volume in actively bleeding patients
Whole Blood
Contraindication: not for patients with severe chronic anemia
Whole Blood
For a 70-kg (154-lb) adult, each unit of whole blood should increase the hematocrit level 3% or hemoglobin 1 g/dL.
Whole Blood
The increase is greater in a smaller person and less in a larger one.
Whole Blood
Preparation: Each unit of pRBC’s contains approximately 250 mL
Red Blood Cells
Prepared by removing 200 to 250 mL of plasma from a unit of WB.
Red Blood Cells
Shelf life: Cells prepared in an open system must be transfused within 24 hours
Red Blood Cells
If cells are prepared using the close system, they have the same expiration date as the original unit of the WB.
Red Blood Cells
Composition: RBC, reduced plasma, WBC and platelets
Red Blood Cells
Average hematocrit: 65-80%
Red Blood Cells
Indication: Increasing RBC mass requiring increased oxygen carrying capacity
Red Blood Cells
Critical level: 6g/dL or less
Red Blood Cells
Contraindication: well compensated patients (chronic renal failure)
Red Blood Cells
RBCs should not be used to treat nutritional anemia such as
o iron deficiency
o pernicious anemia, unless the patient show signs of decompensation (need for increased oxygen carrying capacity)
RBC transfusion is not to be used to enhance general well-being
o promote wound healing
o prevent infection
o expand blood volume when oxygen-carrying capacity is adequate, or prevent future anemia.
Increase:
o Hemoglobin level:
o Hematocrit level:
o Hemoglobin level: 1 g/dL
o Hematocrit level: 3%
In pediatric patients, a dose of 10 to 15 mL/kg will increase:
o Hemoglobin:
Hematocrit:
o Hemoglobin: 2 to 3 g/dL
o Hematocrit: 6% to 9%
Advantages over WB:
1. Equal oxygen carrying capacity in [?]
2. Significant reduction in level of [?] (safe transfusion of group O cells to nongroup O recipients)
3. Significant reduction in levels of [?] in patients with cardiac, renal or liver disease
half volume
isoagglutinin
acid, citrate and potassium load
Average unit of RBC contains approx. 2x109 leukocytes
Leukocyte- Reduced RBCs
Donor leukocytes may cause the following:
[?] transfusion reactions
Transfusion-associated [?]
Transfusion-related [?]
In addition, human leukocyte antigens (HLA) are responsible for [?]
Leukocytes may harbor [?]
Febrile nonhemolytic
graftversus-host disease
immune suppression
HLA alloimmunization
cytomegalovirus
To reduce HLA alloimmunization and CMV transmission, the leukocyte content must be reduced to less than 5 × 106
Leukocyte- Reduced RBCs
Use of leukocyte reduction filters
Leukocyte- Reduced RBCs
Decrease febrile nonhemolytic transfusion reactions
ACCEPTED
Decrease hospital length of stay
CONTROVERSIAL
Decrease alloimmunization to white blood cell antigens
ACCEPTED
Decrease incidence of wound infections postsurgery
CONTROVERSIAL
Decrease transmission of cytomegalovirus (CMV)
ACCEPTED
Decrease incidence of cancer recurrence postsurgery
CONTROVERSIAL
For neonates in the treatment of anemia secondary to spontaneous fetomaternal hemorrhage, obstetric accidents and internal hemorrhage
RBC aliquots
Reduced risk of TAGVHD in patients receiving allogeneic bone marrow transplants
Irradiated RBCs
Preparation: 70% of the original WBCs removed and at least 70% of the original RBC’s are left.
WBC poor RBC
Methods of obtaining leukocyte poor RBCs: centrifugation, filtration and washing
WBC poor RBC
WBC poor RBC
Reduction is done to avoid the following:
- Febrile non-hemolytic transfusion reactions
- HLA alloimmunization
- TRALI
- Transfusion related graft vs host disease
- Transfusion related immune suppression
Shelf-Life: Closed system- same as the original unit of blood; Open system: 24 hours
WBC poor RBC
WBC poor RBC
Donor WBC may harbor:
o CMV
o EBV
o HIV
o HTLV
Therapeutic uses: In addition to increasing RBC mass, leukocyte poor RBC’s also minimize febrile transfusion reactions in patients who have leukocyte antibodies as well as reducing CMV transmission.
WBC poor RBC
Preparation: Plasma is removed from WB after centrifugation
Washed RBC’s
Washing: removes plasma proteins
Washed RBC’s
Shelf Life: Washed RBC’s have a shelf life of 24 hours after the original unit is opened
Washed RBC’s
Stored at 1-6 degrees Celsius
Washed RBC’s